⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Karyon Bio and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Karyon Bio
↗Bengaluru, India (with US presence in Mountain View, California)
Karyon Bio is an AI-driven biotechnology startup focused on the early detection and treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). The company leverages a proprietary platform that integrates multi-omics data, advanced imaging, and machine learning to provide non-invasive diagnostic solutions and personalized therapeutic strategies.
The company aims to reduce reliance on invasive procedures like liver biopsies by developing AI-powered biomarkers and drug discovery workflows. Karyon Bio operates with a focus on precision medicine, aiming to predict disease progression and identify tailored therapeutic options for patients suffering from chronic liver conditions.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:-
Industry:Biotechnology
Sub-Industry:AI-driven diagnostics and drug discovery
SIZE & FINANCIALS
Employees:1-50
Revenue:$0
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Seed
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery
Modalities:AI-driven diagnostics, Biomarker discovery
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Hospitals, genome institutes, and research labs (global collaborations)
COMPETITION
Position:Emerging
Competitors:Various AI-driven drug discovery and liver-focused diagnostic companies
LEADERSHIP
Key Executives:
Srinivas Thirunagari - Founder and CEO
Scientific Founders:Srinivas Thirunagari
LINKS
Website:karyonbio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Karyon Bio. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.